On the opposite, the occurrence of a microangiopathic hemolytic anemia (MAHA), initially reported with bevacizumab but also observed with sunitinib, might be favored by the combination of both agents targeting the VEGF pathway [42–44]. This evidence concerns the gene VEGFA and congenital thrombotic thrombocytopenic purpura.